Review Article

TO SYNTHESIZE THE SIMPLIFIED VANCOMYCIN AND EVALUATION OF ITS ANALOGUES AS NOVEL ANTIBIOTICS

Prof. (Dr.) Satish Kumar Sharma [1], Prateek Porwal [*2], Dilip Kumar Chanchal [3], Gyan Singh [4]

[1]Professor & Dean, Glocal School of Pharmacy, The Glocal University, Mirzapur Pole, Saharanpur - 247001, Uttar Pradesh, India.

[2, 3, 4] PhD. Research Scholar, Glocal School of Pharmacy, The Glocal University, Mirzapur Pole, Saharanpur - 247001, Uttar Pradesh, India.

Corresponding Author:

Mr. Prateek Porwal, PhD. Research Scholar, Glocal School of Pharmacy, The Glocal University, Mirzapur Pole, Saharanpur - 247001, Uttar Pradesh, India.

Email: prateekgupta2525@gmail.com

Abstract

Vancomycin, a unique glycopeptide anti-microbial, was employed as a last option for treating multidrug-safe Gram-positive bacterial diseases. Vancomycin resistance was first noted in France in 1986, about 30 years after it was first administered. This became a significant health problem, requiring the immediate use of elective treatment approaches. Semi-synthetic antibacterial combinations and updated versions of previously utilized antibiotics are two examples of novel particle types. Vancomycin compounds that are semi-synthetic and have better lipid-restricting, film-disturbing, and restricting propensities have shown promise against Gram-positive and Gram-negative microscopic organisms. In this regard, different forms of no hereditary protection against vancomycin and the creation of several efficient strategies to counteract innate resistance in Gram-negative microbes, and acquired resistance in Gram-positive microorganisms, have been discussed.

Keywords: Antibiotics, Vancomycin, Synthesize, microscopic organisms, Gram-negative

1. Introduction

The worldwide expansion of antimicrobial resistance (AMR), which raises morbidity and death rates, poses a severe threat to treating infectious illnesses [1, 2]. The World Health Organization (WHO) Global Antimicrobial Surveillance System revealed that several hazardous bacterial contaminations had significant levels of blocking globally (GLASS) [3-5]. Salmonella spp., Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae are the bacteria that cause blockages most commonly reported [6-8]. A few innovative drugs were approved due to efforts performed by several health organizations and state-run administrations to slow the fast rise of antibiotic resistance [9]. Five new categories of antibiotics have been released into the market: lipopeptides, macrocyclic antibiotics (fidaxomicin), pleuromutilin (retapamulin), and pleuromutilin (daptomycin) [10, 11]. The container class components of bacterial opposition hindered the effectiveness of the other

innovative antibiotics, which were modifications of the prior antibiotics. Drug firms' withdrawal from anti-toxin research left target-based or phenotypic-screening strategies without cutting-edge platforms [12]. This just made the AMR problem worse. Bacterial contamination is a characteristic of "noninherited" immunity to medications that has hitherto received little attention. Antibiotic-resistant bacteria are often phenotypically resistant to them in this circumstance, despite their inherent susceptibility [13]. This phenotypic "noninherited" opposition results from bacteria's ability to create biofilms, induce intracellular illnesses, and enter a metabolically inactive state [14]. AMR is increased by this noninherited resistance, which thus makes treatment exceedingly challenging. The glycopeptide antibiotics showed the most amazing median life duration of all the indicated antibiotic classes [15].

As opposed to proteins, which are more prone to transform, this family of antibiotics blocked the development of peptidoglycans, which are more likely to do so. So there was less chance of blockage [16]. To postpone the inevitable result of a defense mechanism against it, vancomycin was utilized as an anti-infection after all other therapies for complex illnesses brought on by Gram-positive microscopic organisms that are multidrug-safe run out [17].

After vancomycin was initially used in medicine, it took over thirty years before resistance to the drug was found [18]. Researchers from the center and the mainstream have issued concerns about the rise of antimicrobial resistance and have demanded prompt action to stop it. The WHO's 2017 list of essential bacteria places Enterococcus faecium and vancomycin-safe S. aureus (VISA and VRSA) in the high need class of microorganisms since they are both vancomycin-resistant. There are still just a few therapy options available for safe microorganisms [19, 20].

2. Previous studies

S. aureus is a Gram-positive coccus with grape-like bunches, huge, spherical bright yellow states, and beta-hemolysis when cultivated on agar plates. S. aureus may be distinguished from most other staphylococci using the coagulase test. All other staphylococci, including S. epidermis, are coagulase-negative in contrast to S. aureus, which is coagulase-positive. S. epidermidis is white, but the variation S. aureus is a very brilliant yellow [21].

S. aureus is one of the significant contributors to nosocomial infections. S. aureus may cause several different suppurative (discharge framing) infections and toxins in humans. It also brings on urinary tract ailments, pneumonia, mastitis, phlebitis, eye infections, and furuncles. It also has a role in well-known diseases, including osteomyelitis and endocarditis. By injecting superantigens into the circulatory system and contaminating food with enterotoxins, S. aureus causes severe shock conditions. Generally, 15–40% of healthy people are S. aureus carriers. In affluent nations, S. aureus is especially famous for being the most often recognized cause of specific site infections, which raises the mortality rate, the number of days spent in the hospital, and the cost of medical care [22].

Penicillin was released in the middle of 1940, defying expectations about the prevalence of staphylococcal diseases. However, penicillin-safe staphylococci were initially identified in a hospital emergency department and later in a nearby neighborhood as early as 1942. Today, more than 90% of staphylococcal isolates produce penicillinase, notwithstanding the clinical setting [23].

Methicillin, a penicillinase-safe semi-engineered antibiotic that offered defense against

staphylococcus contaminations, was released during the ideal period in the 1960s. Methicillin presentation, however, was shortly surpassed by methicillin-safe confines. Methicillin resistance is a portable hereditary factor resulting from the mecA operon, carried by the staphylococcal tape chromosome mec (SCCmec). Local area-related MRSA (CA-MRSA) initially surfaced at the end of the 1990s. Since then, locally and in the medical clinic, it has rapidly grown [24].

Vancomycin middle of the road S. aureus (VISA) are defined as S. aureus isolates with vancomycin MICs between 4 and 8 g/ml, and those with MICs less than 16 g/ml are defined as vancomycin safe, according to the most current CLSI standards. Most S. aureus strains should be killed by vancomycin at concentrations between 0.5 and 2 mg/l. VISA strains, in contrast to VRSA, lack vancomycin-safe traits of Vana, vanB, or vanC. Whatever the case, the specific composition of VISA type resistance is still a mystery. However, other hypotheses for a secure system similar to VISA have been made, one of which addresses DNA confusion issues. The acquisition of VISA aggregation is most likely the result of modifications to the peptidoglycan union pathways. VISA strains have also generated a high quantity of D-alanine-D-alanine residues. These new cell wall layers prevent Vancomycin atoms from blocking their intended destinations [25, 26].

3. Glycopeptides Progenitors

Antibiotics called glycopeptides are a crucial family of drugs that stop the growth of cell walls. They are glycosylated heptapeptides with a tricyclic or tetracyclic nonribosomal peptide core made by a swarm of soil actinomycetes [27]. The glycopeptides are broken down into five primary subclasses, I through V, since the amino acids 1 and 3 in the heptapeptide contain corrosive deposits of amino acids. Compounds like vancomycin, actinidin A, ristocetin A, teicoplanin, and compstatin, to mention a few, are included in these subclasses. 6 Eli Lilly developed the first antibiotic in this class, vancomycin, in 1953, and it was given the go-ahead to be used in 1958 [28]. Another medically necessary particle is teicoplanin, which was discovered in 1978 and was licensed for use in clinical trials in Europe in 1988. Vancomycin belongs to subclass I of the amino acid categorization system because it contains two aliphatic and five aromatic amino acids [29].



Figure 1: Acquired resistance to vancomycin; VSSA [30]

The lipoglycopeptide teicoplanin is composed of a lengthy unsaturated lipid chain joined to the glucosamine sugar and seven aromatic amino acids (Figure 1) [31]. The primary ingredient in the therapeutic combination of teicoplanins A2-1 to A2-5 is teicoplanin A2-2. Since S. Aureus is safe for methicillin, these drugs, particularly vancomycin, are essential in treating life-threatening illnesses (MRSA). Vancomycin has been advocated intravenously for treating circulatory system diseases, skin structure infections, and endocarditis caused by MRSA [32].

Despite vancomycin's advantages, its intravenous administration was previously linked to various adverse effects, including nephrotoxicity, red man syndrome, and ototoxicity, which have subsequently been removed as a result of better cleaning techniques. Compared to other glycopeptide antibiotics, it has relatively poor pharmacokinetics (half-life = 4–11 h) and tissue penetration characteristics [33]. Teicoplanin sometimes outperforms vancomycin because of its superior effectiveness and tolerability against various clinically significant infections of the Enterococcus, Staphylococcus, and Streptococcus genera. It has a longer half-life and may be administered intravenously or intramuscularly for control (30 hours) [34].

4. Instrument of Action

Glycopeptide antibiotics block transglycosylation and transpeptidation in the latter extracytoplasmic stages of cell wall synthesis by limiting their activities to the D-Ala-D-Ala moiety of the peptidoglycan precursors (lipid II and juvenile peptidoglycan) [35]. Five hydrogen bonds, hydrophobic forces stabilise this combination of D-Ala-D-Ala-terminated glycopeptide antibiotics, and van der Waals forces [36]. The tendency of vancomycin to form consecutive dimers increases the limiting partiality of the substrate. Vancomycin's limiting constant at the DAla-D-Ala terminal is 4.4×10^5 M. Vancomycin produces dimers, although teicoplanin does not [37]. The lipophilic portion of teicoplanin, which promotes adhesion and hence inhibits interaction with the substrate, provides the extra film mooring qualities [38]. Compared to compound-targeting antibiotics, which are readily rendered ineffective due to genetic alterations, glycopeptide antibiotics are less prone to assault because of their mode of action [39, 40].

5. Obstruction Development

In France in 1986, Enterococcus faecalis was the main contributor to vancomycin resistance. Due to the medication's steadily rising usage in clinical settings, the spread of vancomycin-safe Enterococci (VRE), an aggressive colonizer, has surged in the USA. Most likely due to the abuse of avoparcin, it happened in European networks (another glycopeptide anti-microbial, utilized as a development advertiser in livestock). Later, in 1996, vancomycin resistance in S. aureus that was first identified in a newborn infant brought to a hospital emergency department in Japan had reduced. This vancomycin-moderate S. aureus (VISA) strain (Mu50), which has an 8 g mL vancomycin MIC1, has been functioning like a regular VISA strain since being isolated [41, 42].

According to a 2002 report, the first instance of high vancomycin obstruction in S. aureus, also known as vancomycin-safe S. aureus (VRSA), or clinical detach with MIC > 32 g mL-1 and VRE (vanA positive, vancomycin opposition quality bunch), that could be distinguished from a catheter-related disease in a hospitalized patient from the USA [43].

If an S. aureus strain contains subpopulations of cells that flourish on a BHI agar plate with 4 g of vancomycin, it is referred to as a hetero-VISA (hVISA) strain. In contrast, the MICs for

VISA and VRSA are 4 g, 8 g, and 16 g mL-1 in stock weakening, respectively. The supporting data discusses Vancomycin resistance in further depth, including the natural barrier present in Gram-negative bacteria [44, 45].

5.1. Resistance was attained. Vancomycin protection was achieved thanks to the completion of peptidoglycan precursors.

D-Ala-D-Ala, which has a shallow inclination, D-Ala-D-Lac and D-Ala-D-Ser have more significant connections to vancomycin (Figure 2) [46]. Vancomycin protection for enterococci is currently known to be provided by 11 separate quality groups. D-Alat-Lac is encoded by VanA, VanB, VanD, Vanf, Vani, and Vanm [47].



Figure 2: Vancomycin-resistant bacteria can be treated with clinically tested antibiotics. [48]

There are ties between the vanC, vanE, vanG, vanL, and vanN factions and the D-Ala/D-Ser opposition. Genes in the vanA and vanB quality clusters are those that are most often detected [49]. These peptidoglycan precursors increase the target peptide's sensitivity to vancomycin by a 1000-overlap failure, followed by a gradual increase in the demand for 102 M1. The homologs for D-Ala-D-Lac intervened resistance, and variants of three negative qualities, namely van, vanX, and vanA, may be found in the vanA and vanB quality bunches. When vancomycin, teicoplanin, or other substances that irritate cell wall precursors are present, the VanS protein (a layer-related sensor kinase) undergoes autophosphorylation [50]. VanR, a protein that controls cytoplasmic processes and promotes transcription, is therefore phosphorylated. The VanR creates the declaration of the VanR and VanS qualities in addition to managing the articulation of the opposing traits of the VanA and VanB clusters and linking to the VanHAX center [51]. VanH encodes a D-lactate dehydrogenase, which transforms pyruvate into D-Lac, whereas VanX encodes a D, Ddipeptidase, which hydrolyzes D-Ala to D-Ala. The gene VanA and its homologs encode a ligase that results in D-Ala-D-Lac [52]. A D,D-carboxypeptidase is produced by the gene vanY, which is present in both the vanA and

vanB groups. The D-Ala is released at the C-end of late layer bound peptidoglycan precursors [53]. Additionally, the vanA and vanB groups have low-level teicoplanin resistance thanks to a protein produced by the vanZ gene [54]. It has only recently been shown that vancomycin-safe bacteria can produce a single VanXY molecule, which can inhibit both D,D-dipeptidase and D,D-pentapeptidase activities [55].

Vancomycin resistance occurs in VISA as a consequence of the bacterial cell wall thickening. Overall, it seems that the two two-part tangible administrative frameworks that control the record of qualities in cell wall biosynthesis are affected directly or indirectly by the relevant altering qualities (walkR framework and yvqF/vraSR framework) [56]. But the RNA polymerase quality protein rpoB also changed in VISA isolates. It has been shown that in addition to these features, -lactamase-encoding traits also contribute to the VISA phenotype. Common traits include an excessive amount of cell wall material, an unequal division of female cells during cell division, and slow autolysis rates are prohibited by VISA. These modified anomalies' atomic origin has yet to be determined [57]. Cell walls in VISA segregates are thicker and have an irregular shape because to the exceptionally high amounts of peptidoglycan production. Recent research on VISA strains has shown that enhanced arginine catabolism, which is controlled by the two-part administrative systems VraSR and GraRS, compensates for increased cell wall biosynthesis in VISA (Mu50 heritage) [58]. It would need additional investigation to determine if this globally pervasive trait is brought on by VISA variations with various ancestries [59]. The thicker cell wall contained more D-alanyl-D-alanine side chains without crosslinks and less peptidoglycan crosslinking [60]. Vancomycin entirely eliminates the VISA/VRSA research facility freak strains' way of life [61]. The remaining free vancomycin particles are blocked from advancing farther within by the vancomycin attached to D-Ala, which serves as a barrier [62]. Analysis of the genotype of VRSA revealed that VRE was the origin of its resistance traits. In certain types of VRSA, resistance was assumed to result from both thickening of the cell wall and altered pentapeptide ends [63].

5.2. Characteristic Resistance in Gram-Negative Bacteria.

Gram-negative bacteria have an additional layer on their surface that acts as a wall to keep out hydrophilic materials like glycopeptides [64]. They are also too big and have a high subatomic weight to pass through the porins of the outer layer and get to the cell wall. As a consequence, Gram-negative bacteria develop their distinctive glycopeptide resistance [65].

6. Conclusion

Our research shows that in order to achieve the two desired improvements, vancomycin's R2NHR1 substituents have to be coupled to it via an amide. The method may be effectively used in an iterative manner to deal create libraries of analogues with a superior in vitro restorative file against VRE, MRSA, and C. difficile as possible cutting edge vancomycin analogues for beneficial application. Vancomycin is a human medication with a significant demand for infection prevention, according to the WHO. One class of antibiotics is no longer useful in treating severe infections due to glycopeptide protection. This point of view provides an overview of the fundamental methods used to maintain and handle vancomycin-safe microorganisms. To overcome this learned limitation, many methods have been researched. Among the successful tactics were improvements to film interruption capability, lipid restricting characteristics, and limiting inclination to the changed target peptide.

7. References

1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb 12;399(10325):629-55.
2. Smith RD, Coast J. Antimicrobial resistance: a global response. Bulletin of the World Health Organization. 2002;80:126-33.
3. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. Journal of global infectious diseases. 2019 Jan;11(1):36.
4. Murphy HM, Prioleau MD, Borchardt MA, Hynds PD. Epidemiological evidence of groundwater contribution to global enteric disease, 1948–2015. Hydrogeology Journal. 2017 Jun;25(4):981-1001.
5. Maillard JY, Bloomfield SF, Courvalin P, Essack SY, Gandra S, Gerba CP, Rubino JR, Scott EA. Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paper. American journal of infection control. 2020 Sep 1;48(9):1090-9.
6. Alavi M, Rai M. Recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug-resistant (MDR) bacteria. Expert review of anti-infective therapy. 2019 Jun 3;17(6):419-28.
7. AL-Mjalawi BS, AL-Hamil AR, AL-Awade HA. Study the inhibition activity of Bifidobacterium spp. Filtrate Against Some Pathogenic Bacteria Isolated From Patients With Cardiac Catheterization In-Vitro. International Journal Of Research And Development In Pharmacy & Life Sciences. 2016 May 15;5(3):2099-106.
8. Hindi NK, Al-Mahdi ZK, Chabuck ZA. Antibacterial activity of the aquatic extractof fresh, dry powder ginger, apple vinegar extract of fresh ginger and crud oil of ginger (zingiberofficinale) against different types of bacteria in Hilla City, Iraq. Prostate. 2014;3(6).
9. Sharma D, Sharma J, Deo N, Bisht D. Prevalence and risk factors of tuberculosis in developing countries through health care workers. Microbial pathogenesis. 2018 Nov 1;124:279-83.
10. Wright GD. Antibiotics: a new hope. Chemistry & biology. 2012 Jan 27;19(1):3-10.
11. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. The Journal of antibiotics. 2013 Oct;66(10):571-91.
12. Garland MM. Chemical Tools to Interrogate and Inhibit Bacterial Exotoxins. Stanford University; 2021.
13. Acharya Y, Bhattacharyya S, Dhanda G, Haldar J. Emerging Roles of Glycopeptide Antibiotics: Moving beyond Gram-Positive Bacteria. ACS Infectious Diseases. 2021 Dec 8;8(1):1-28.
14. Soares A, Alexandre K, Etienne M. Tolerance and persistence of Pseudomonas aeruginosa in biofilms exposed to antibiotics: Molecular mechanisms, antibiotic strategies and therapeutic perspectives. Frontiers in microbiology. 2020 Aug 27;11:2057.
15. Baquero F, Martinez JL, F. Lanza V, Rodríguez-Beltrán J, Galán JC, San Millán A, Cantón R, Coque TM. Evolutionary pathways and trajectories in antibiotic resistance.

Clinical Microbiology Reviews. 2021 Dec 1;34(4):e00050-19.

16. Culp EJ, Waglechner N, Wang W, Fiebig-Comyn AA, Hsu YP, Koteva K, Sychantha D, Coombes BK, Van Nieuwenhze MS, Brun YV, Wright GD. Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling. Nature. 2020 Feb;578(7796):582-7.
17. Murat-Bors A. Modern assumptions of the American ballistic missile defence system against the background of historical concepts and programmes. Security and Defence Quarterly. 2018;22(5):99-131.
18. Martens E, Demain AL. The antibiotic resistance crisis, with a focus on the United States. The Journal of antibiotics. 2017 May;70(5):520-6.
19. Roope LS, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, Butler CC, Tan PS, Walker AS, Robotham JV, Wordsworth S. The challenge of antimicrobial resistance: what economics can contribute. Science. 2019 Apr 5;364(6435):eaau4679.
20. Chandler CI. Current accounts of antimicrobial resistance: stabilisation, individualisation and antibiotics as infrastructure. Palgrave communications. 2019 May 21;5(1):1-3.
21. Aruna V. Comparative Study of Inducible and Constitutive Clindamycin Resistance among Methicillin Resistant Staphylococcus Aureus Isolates (Doctoral dissertation, Coimbatore Medical College, Coimbatore).
22. Bryan CS. The pathogenesis of infectious diseases. Textbook of Family Medicine E-Book. 2015 Feb 2;201:183.
23. Christopher KC, Rita WY, Leung SS, Mamie HU, Ip M. Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches–an overview. Advanced Drug Delivery Reviews. 2021 Dec 9:114078.
24. Xu L, Liang W, Wen Y, Wang L, Yang X, Ren S, Jia N, Zuo X, Liu G. An ultrasensitive electrochemical biosensor for the detection of mecA gene in methicillin-resistant Staphylococcus aureus. Biosensors and Bioelectronics. 2018 Jan 15;99:424-30.
25. Nasaj M, Farmany A, Shokoohizadeh L, Jalilian FA, Mahjoub R, Roshanaei G, Nourian A, Shayesteh OH, Arabestani MR. Development of Chitosan-Assisted Fe3O4@ SiO2 Magnetic Nanostructures Functionalized with Nisin as a Topical Combating System against Vancomycin-Intermediate Staphylococcus aureus (VISA) Skin Wound Infection in Mice. Journal of Nanomaterials. 2022 Apr 28;2022.
26. Blondeau JM, Sanche SE, Shebelski SD, Mckinnon D. Oral Session. International Journal of Antimicrobial Agents. 2017;50(S2):S29-68.
27. Chen S, Wu Q, Shen Q, Wang H. Progress in understanding the genetic information and biosynthetic pathways behind Amycolatopsis antibiotics, with implications for the continued discovery of novel drugs. ChemBioChem. 2016 Jan;17(2):119-28.
28. Dhanda G, Sarkar P, Samaddar S, Haldar J. Battle against vancomycin-resistant bacteria: recent developments in chemical strategies. Journal of medicinal chemistry. 2018 Nov 7;62(7):3184-205.
29. Kisil OV, Efimenko TA, Efremenkova OV. Looking back to Amycolatopsis: history of the antibiotic discovery and future prospects. Antibiotics. 2021 Oct 15;10(10):1254.
30. Gaillard T, Dupieux-Chabert C, Butin M, Dumitrescu O, Naceur O, Bouveyron C,

Martra A, Bes M, Tristan A, Vandenesch F, Lina G. Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure. Journal of Antimicrobial Chemotherapy. 2022 Apr;77(4):1032-5.

31. Sarkar P, Yarlagadda V, Ghosh C, Haldar J. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Medchemcomm. 2017;8(3):516-33.
32. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, Holland TL, Fowler VG. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nature Reviews Microbiology. 2019 Apr;17(4):203-18.
33. Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. The Journal of Antibiotics. 2014 Sep;67(9):631-44.
34. Kang HK, Park Y. Glycopeptide antibiotics: structure and mechanisms of action. Journal of Bacteriology and Virology. 2015 Jun 1;45(2):67-78.
35. Kumar S, Mollo A, Kahne D, Ruiz N. The Bacterial Cell Wall: From Lipid II Flipping to Polymerization. Chemical Reviews. 2022 Mar 11;122(9):8884-910.
36. Ismail OH, Ciogli A, Villani C, De Martino M, Pierini M, Cavazzini A, Bell DS, Gasparrini F. Ultra-fast high-efficiency enantioseparations by means of a teicoplanin-based chiral stationary phase made on sub-2 μm totally porous silica particles of narrow size distribution. Journal of Chromatography A. 2016 Jan 4;1427:55-68.
37. Gell DA, Grant RP, Mackay JP. The detection and quantitation of protein oligomerization. Protein Dimerization and Oligomerization in Biology. 2012:19-41.
38. Peluso P, Chankvetadze B. Recognition in the Domain of Molecular Chirality: From Noncovalent Interactions to Separation of Enantiomers. Chemical Reviews. 2022.
39. Kamaruzzaman NF, Tan LP, Hamdan RH, Choong SS, Wong WK, Gibson AJ, Chivu A, Pina MD. Antimicrobial polymers: the potential replacement of existing antibiotics?. International Journal of Molecular Sciences. 2019 Jun 4;20(11):2747.
40. Álvarez-Martínez FJ, Barrajón-Catalán E, Encinar JA, Rodríguez-Díaz JC, Micol V. Antimicrobial capacity of plant polyphenols against gram-positive bacteria: A comprehensive review. Current medicinal chemistry. 2020 May 1;27(15):2576-606.
41. Perveen I, Majid A, Knawal S, Naz I, Sehar S, Ahmed S, Raza MA. Prevalence and antimicrobial susceptibility pattern of methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococci in Rawalpindi, Pakistan. British Journal of Medicine and Medical Research. 2013 Jan 1;3(1):198.
42. Reyes J, Rincón S, Díaz L, Panesso D, Contreras GA, Zurita J, Carrillo C, Rizzi A, Guzmán M, Adachi J, Chowdhury S. Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clinical infectious diseases. 2009 Dec 15;49(12):1861-77.
43. Friães A, Resina C, Manuel V, Lito L, Ramirez M, Melo-Cristino J. Epidemiological survey of the first case of vancomycin-resistant Staphylococcus aureus infection in Europe. Epidemiology & Infection. 2015 Mar;143(4):745-8.
44. Sader HS, Fey PD, Fish DN, Limaye AP, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine US medical centers from 2002 to 2006. Antimicrobial agents

and chemotherapy. 2009 Oct;53(10):4127-32.

45. Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Scientific reports. 2020 Jul 29;10(1):1-6.
46. Rahman M, Kaiser F, Jamshidi S, Freitas Monteiro M, Rahman KM, Mullany P, Roberts AP. Integron gene cassettes harboring novel variants of d-alanine-d-alanine ligase confer high-level resistance to d-cycloserine. Scientific reports. 2020 Nov 26;10(1):1-6.
47. Alam M, Bano N, Ahmad T, Sharangi AB, Upadhyay TK, Alraey Y, Alabdallah NM, Rauf MA, Saeed M. Synergistic Role of Plant Extracts and Essential Oils against Multidrug Resistance and Gram-Negative Bacterial Strains Producing Extended-Spectrum β-Lactamases. Antibiotics. 2022 Jun 26;11(7):855.
48. Varela AR, Ferro G, Vredenburg J, Yanık M, Vieira L, Rizzo L, Lameiras C, Manaia CM. Vancomycin resistant enterococci: from the hospital effluent to the urban wastewater treatment plant. Science of the Total Environment. 2013 Apr 15;450:155-61.
49. Ammam F, Meziane- cherif D, Mengin- Lecreulx D, Blanot D, Patin D, Boneca IG, Courvalin P, Lambert T, Candela T. The functional vanGCd cluster of C lostridium difficile does not confer vancomycin resistance. Molecular microbiology. 2013 Aug;89(4):612-25.
50. Graham K, Stack H, Rea R. Safety, beneficial and technological properties of enterococci for use in functional food applications–a review. Critical Reviews in Food Science and Nutrition. 2020 Dec 15;60(22):3836-61.
51. Groisman EA. Feedback control of two-component regulatory systems. Annual Review of Microbiology. 2016 Sep 9;70:103.
52. López-Colomé AM, Lee-Rivera I, Benavides-Hidalgo R, López E. Paxillin: a crossroad in pathological cell migration. Journal of hematology & oncology. 2017 Dec;10(1):1-5.
53. Tanimura S, Takeda K. ERK signalling as a regulator of cell motility. The Journal of Biochemistry. 2017 Sep 1.
54. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013 Jan;493(7432):346-55.
55. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell death & disease. 2010 Feb;1(2):e29-.
56. Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S. WalK (S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108. Journal of Antimicrobial Chemotherapy. 2017 Apr 1;72(4):1006-13.
57. Mediati DG, Wong JL, Gao W, McKellar S, Pang CN, Wu S, Wu W, Sy B, Monk IR, Biazik JM, Wilkins MR. RNase III-CLASH of multi-drug resistant Staphylococcus aureus reveals a regulatory mRNA 3′ UTR required for intermediate vancomycin resistance. Nature communications. 2022 Jun 22;13(1):1-5.

58. Matsuo M, Cui L, Kim J, Hiramatsu K. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrobial agents and chemotherapy. 2013 Dec;57(12):5843-53.
59. Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, Cui L, Matsuo M, Aritaka N, Hiramatsu K. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrobial agents and chemotherapy. 2014 Sep;58(9):5024-35.
60. Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infection, Genetics and Evolution. 2014 Jan 1;21:575-82.
61. McCallin S, Menzi C, Lassen S, Daraspe J, Oechslin F, Moreillon P. Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA). Antimicrobial Agents and Chemotherapy. 2022 Jul 19;66(7):e02247-21.
62. Dhanda G, Sarkar P, Samaddar S, Haldar J. Battle against vancomycin-resistant bacteria: recent developments in chemical strategies. Journal of medicinal chemistry. 2018 Nov 7;62(7):3184-205.
63. Acharya Y, Dhanda G, Sarkar P, Haldar J. Pursuit of next-generation glycopeptides: a journey with vancomycin. Chemical Communications. 2022;58(12):1881-97.
64. Rashid M, Rabbi MA, Ara T, Hossain MM, Islam MS, Elaissari A, Ahmad H, Rahman MM. Vancomycin conjugated iron oxide nanoparticles for magnetic targeting and efficient capture of Gram-positive and Gram-negative bacteria. RSC advances. 2021;11(57):36319-28.
65. Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, Mohsen Y, Adukkadukkam S, Awuah WA, Jose RA, Sylvia N. Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics. 2022 Feb 4;11(2):200.